ClinicalTrials.gg
Active, not recruitingNCT06205706Updated Sep 19, 2025

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

A Phase 1/2 interventional study of BI-1910 and Pembrolizumab in Solid Tumors, Non Small Cell Lung Cancer and Hepatocellular Carcinoma, sponsored by BioInvent International AB. Active, not recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by BioInvent International AB · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain — 160 open to participants now, 333 under way, 112 of them phase 3. Carcinoma, Non-Small-Cell Lung · Spain.

Enrollment
718th of 797
35 · median 188
Started
2023
with 57 others
Phase 1/2
123 of 851
34 open now
Primary completion
2027-07
later than 158 of 332 live
Registered
702nd of 851
by date

Among the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, this one is the 718th largest by enrollment of the 797 interventional ones that give a count, is one of 58 that started in 2023, is one of 123 in phase 1/2, reaches primary completion later than 158 of the 332 other live ones, and was the 702nd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

160 of the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, or all of them as a file.
02

Study summary

The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy.

The main questions it aims to answer are:

  • how safe and tolerable is BI-1910
  • what is maximum tolerated or administrated dose
  • to determine recommended dose for further clinical trials

Participants will receive infusions of BI-1910 alone or combination with pembrolizumab every 3 weeks.

Read the detailed description

This is a Phase 1/2a, open-label, dose-escalation, multicenter, FIH, consecutive-cohort, clinical trial of BI-1910, as a single agent and in combination with pembrolizumab, in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy.

The trial comprises 2 phases: a Phase 1 with Parts A and B, and a Phase 2a with Parts A and B.

Phase 1 Part A consists of a dose escalation of BI-1910 as a single agent to evaluate safety and tolerability and to determine the RP2D as a single agent (sRP2D) in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy.

Phase 1 Part B consists of a dose escalation of BI-1910 in combination with pembrolizumab to evaluate the safety and tolerability of the combination treatment and to allow selection of the RP2D for BI-1910 in combination with pembrolizumab (cRP2D) in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy.

Phase 2a will assess BI-1910 administered as a single agent (Part A) and in combination with pembrolizumab (Part B) at the respective hypothesized RP2D(s) determined in Phase 1. Phase 2a expansion will be conducted in indication specific cohorts of subjects. The aim of the Phase 2a is to urther assess the safety and tolerability of BI-1910 as a single agent (Part A) and in combination with pembrolizumab (Part B), characterize its PK and pharmacodynamics, and assess preliminary antitumor activity by ORR, DoR, and progression-free survival (PFS), as measured by RECIST v1.1 and iRECIST.

03

Conditions studied

  • Solid Tumors
  • Non Small Cell Lung Cancer
  • Hepatocellular Carcinoma

Keywords

  • solid tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is willing and able to provide signed for the trial.
  2. Is ≥18 years of age on the day of signing the informed consent form.
  3. Has a -confirmed advanced/ solid tumor.
  4. Has received standard of care and progressed or is intolerant of, or is not eligible to receive standard of care antineoplastic therapy.
  5. Has at least 1 lesion as defined by v1.1.
  6. Must be willing to provide tumor as specified in the schedule of assessments
  7. Has a of ≥12 weeks.
  8. Has an (ECOG) performance status of 0 or 1.
  9. Has adequate organ function as confirmed by laboratory values.

Exclusion criteria

Exclusion Criteria:

  1. Needs doses of prednisolone >10 mg daily (or equipotent doses of other ) while on the trial other than as premedication.
  2. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  3. Has known or suspected to BI-1910 or pembrolizumab.
  4. Has cardiac or renal amyloid light-chain amyloidosis.
  5. Has received the following:

    1. Chemotherapy or small molecule anti-cancer therapy products within 4 weeks, or 5 half-lives of the respective drug whichever is longer, of first dose of BI-1910.
    2. Radiotherapy within 2 weeks of first dose of BI-1910. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) for non-CNS disease.

      Subjects who have previously had radiation pneumonitis are not allowed.

    3. Immunotherapy within 4 weeks prior to the first dose of BI-1910.
  6. Has not recovered from AEs to at least Grade 1 by National Cancer Institute (NCI) (CTCAE) (v5.0 or higher).
  7. Has had Grade ≥3 manifestations of previous treatments (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4).
  8. Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
  9. Has an active, known, or suspected autoimmune disease.
  10. Is a female subject and has the ability to become pregnant (or already pregnant or lactating/breastfeeding). However, those female subjects who have a negative serum or urine pregnancy test up to 72 hours prior to their first dose of study treatment and agree to use a highly effective method of for 4 weeks before entering the trial, during the trial, and for 12 months after their last dose of study treatment are considered eligible.
  11. Is a male subject with partner(s) of (unless he agrees to use a barrier method of contraception [condom plus spermicidal gel] with the female partner(s) who are using one highly effective method of contraception during the trial and for 12 months after completing treatment).
  12. Has had major surgery from which the subject has not yet recovered.
  13. Is at high medical risk because of nonmalignant systemic disease including severe active infections on treatment with antibiotics, antifungals, or antivirals other than the ones considered adequate for treatment of .
  14. Has presence of chronic .
  15. Has had an allogenic tissue/solid organ transplant.
  16. Is positive for (HIV).
  17. Has history of chronic HBV or infections.
  18. Has a history of active tuberculosis (Bacillus tuberculosis).
  19. Has received a within 30 days before the first dose of study treatment.
  20. Has uncontrolled or significant cardiovascular disease.
  21. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the trial.
  22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
  23. Is participating or planning to participate in another interventional clinical trial or has participated in a trial of an agent or has used an investigational device within 4 weeks prior to first dose of study treatment.
  24. Has a known additional of another type, with the exception of adequately treated cone-biopsied carcinoma in situ and basal or squamous cell carcinoma of the skin. Male subjects with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for >1 year prior to start of study treatment are eligible.
  25. Has a confirmed diagnosis of primary immunodeficiency or an acquired condition that leads to an immunodeficiency disorder or taking any other form of therapy within 7 days prior the first dose of study treatment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Phase I, Part A - Dose escalation and safety of BI-1910 as single agent

    Dose escalation of BI-1910 administered as a single agent.

    Drug: BI-1910

  • Experimental
    Phase I, Part B - Dose escalation and safety of BI-1910 in combination with pembrolizumab

    Dose escalation of BI-1910 in combination with pembrolizumab.

    Drug: BI-1910 · Drug: Pembrolizumab

  • Experimental
    Phase 2a, Part A - Dose expansion of BI-1910 as single agent

    BI-1910 administered as a single agent at the hypothesized recommended phase 2 dose determined in Phase 1.

    Drug: BI-1910

  • Experimental
    Phase 2a, Part B - Dose expansion of BI-1910

    BI-1910 administered in combination with pembrolizumab at the respective hypothesized recommended phase 2 doses determined in Phase 1

    Drug: BI-1910 · Drug: Pembrolizumab

Interventions

  • DrugBI-1910

    BI-1910 administered as a flat-dose IV infusion once every 3 weeks

  • Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events (AEs)

    AEs will be assessed by the investigators by severity and will be graded according to the NCI CTCAE v5.0 or higher and causality between AEs and the exposure to the study treatment.

    Time frame: From the start of the study treatment for up to 2 years and 90 days.

  2. Occurrence of serious adverse events (SAEs)

    SAEs will be assessed by the investigators by severity and will be graded according to the NCI CTCAE v5.0 or higher and causality between SAEs and the exposure to the study treatment

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  3. Frequency of AEs leading to discontinuation of study treatment

    All adverse events leading to premature study treatment discontinuation will be analyzed descriptively utilizing corresponding MedDRA, System Organ Classes, and Preferred Terms.

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  4. Frequency of dose interruptions and dose reductions.

    Study treatment modifications will be summarized in 2 categories: dose reduction and dose interruptions. The number and percentage of subjects who have any dose reduction or interruption and have at least 1 dose reduction or interruption will be summarized. Lastly, the primary reason for each form of study treatment modification will also be summarized.

    Time frame: From the start of the study treatment for up to 2 years

  5. Changes from baseline in laboratory parameters

    These include clinical laboratory assessments (hematology, clinical chemistry, urinalysis), additional CRP assessment, coagulation, thyroid, pregnancy, and viral serology assessments Safety laboratory results will be graded by NCI CTCAE v5.0 (or higher). If no grading exists, values will be classified into low/normal/high based on laboratory normal ranges. Each parameter will be presented by descriptive statistics at each visit, including change from baseline.

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  6. Changes from baseline in temperature (C or F)

    Temperature (C or F) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline.

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  7. Changes from baseline in Respiratory Rate (Breaths/Min)

    Respiratory rate (breaths/min) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline.

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  8. Changes from baseline in Blood Pressure (mmHg)

    Systolic and diastolic blood pressure (mmHg) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline.

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  9. Changes from baseline in O2 Saturation (%)

    O2 Saturation (%) will be measured in a seated or supine position after 5 minutes' rest and will be summarized by descriptive statistics at each visit, including change from baseline.

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  10. Changes from baseline in weight

    Weight (kg or lb) and body surface area (m2) will be collected at Screening and on each dose day before any study treatment is administered and will be summarized by descriptive statistics at each visit, including change from baseline. Height (cm or in) will be recorded at baseline only

    Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  11. Occurrence of dose limiting toxicities (DLTs)

    All adverse events meeting the DLT criteria will be considered a DLT potentially related to the study treatment, regardless of Investigator/Sponsor causality assessment, excluding toxicities that are clearly related to disease progression or inter-current illness. DLTs will be considered by the safety monitoring committee for the purposes of dosing decisions.

    Time frame: During phase 1 Part A: from the first dose of BI-1910 for 21 days. During phase 1 part B: from the first dose of BI-1910 for 42 days.

  12. identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safety

    based on the totality of the efficacy, safety, PK, and pharmacodynamic endpoints

    Time frame: During phase 2a from screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

Secondary outcomes

  1. Maximum Concentration (Cmax) of BI-1910

    Maximum concentration (Cmax), obtained directly from the observed concentration-versus-time data will be determined.

    Time frame: From the start of the study treatment for up to 2 years and 90 days.

  2. Serum concentration-time curve [AUC] of BI-1910

    Area under the serum concentration-time curve will be determined.

    Time frame: From the start of the study treatment for up to 2 years and 90 days.

  3. Terminal half-life (t½) of BI-1910

    Terminal half-life will be determined, a minimum of 3 points will be used for estimation

    Time frame: From the start of the study treatment for up to 2 years and 90 days.

  4. Recommended dose range (RDR)

    RDR is defined as the range between the minimal reproducibly active dose (MRAD), and the MTD or MAD. MRAD is the lowest dose level at which subjects experience tumor shrinkage and/or relevant PK/pharmacodynamic parameters indicate biological activity.

    Time frame: During phase 1 From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

  5. Incidence and titer of antidrug antibodies (ADAs).

    The detection and characterization of antibodies to BI-1910 will be performed. The samples collected will also be evaluated or BI-1910 serum concentration to enable interpretation of the antibody data. Antibodies may be further characterized and/or evaluated for their ability to neutralize the activity of the study treatments.

    Time frame: From the start of the study treatment for up to 2 years and 90 days.

  6. Objective response rate (ORR).

    Objective response rate based on the best objective response, defined as achieving confirmed CR and/or PR measured by RECIST 1.1 and iRECIST,

    Time frame: During phase 2a from from the start of the study treatment for up to 2 years and 30 days

  7. Duration of response (DoR).

    Defined as the time from the first assessment of PR or CR to the follow-up first assessment of PD measured by RECIST 1.1 and iRECIST.

    Time frame: During phase 2a from from the start of the study treatment for up to 2 years and 30 days

07

Study locations

8 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jul 2027, 43 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 43 months is below that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 16, 2024
StartActual
Dec 4, 2023
Primary completionEst.
Jul 14, 2027
CompletionEst.
Nov 7, 2028
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06205706
Lead sponsor
BioInvent International AB
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Dec 4, 2023
Primary completion
Jul 14, 2027 (estimated)
Completion
Nov 7, 2028 (estimated)
Last update
Sep 19, 2025

Study contacts

Andres McAllister, PhD
study director · BioInvent International AB

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion